The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies.

Abstract excerpt

RAS oncoproteins have been considered undruggable for decades. However, recent advances have led to the development of a large variety of RAS inhibitors. While a multitude of drugs is currently under clinical evaluation, some of them have already been approved in specific contexts, leading to a continuous improvement of available therapeutic options for patients with RAS-mutant cancers. In this Viewpoint, we...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Alleles
• Share to Antineoplastic Agents
• Share to KRAS gene